Leerink initiated coverage of Larimar Therapeutics with an Outperform rating and $25 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- 5 Stocks that Analysts Love in March 2024
- Larimar Therapeutics provides update on nomlabofusp development
- Larimar Therapeutics reports Q4 EPS (30c), consensus (25c)
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
- 3 Best Stocks to Buy Now, 3/12/2024, According to Top Analysts